What's interesting is that the Phase 2 India results were completed and officially announced before Tom Moore's resignation, so the company has always had the science and the trials that Tom Moore led tuned out to be what built on our success. Because of the India Phase 2 trial rests that impressed the GOG, the GOG decided to sponsor additional trials with ADXS which in large part got us to where we are today. What IMO was Tom Moore's big misstep was after the India cervical cancer trial putting all the company's financial resources in a CIN trial to address pre cervical cancer indications. Ultimately too many patients dropped out because simple outpatient surgery was more than 90% effective and ADXS was left with "unreadable" results which Tom Moore sat on for months after he he initially said he would release the results...when he finally did things unravelled financially. So while DO has done a lot, the science has always been there and DO inherited strong Phase 2 data to work with but had to clean up the mess financially and strategically.
News 
Market Data 
Discover 
